8
Mar
2016
Subscribers, Come Celebrate at the TR One-Year Anniversary Party!
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Mar
2016
Draft Joe Biden and Roy Vagelos for a Fair Deal on Drug Pricing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Mar
2016
Trump’s So-Called Healthcare Plan, Valeant Boss Returns, and Gilead’s Good Week
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Feb
2016
Merck, NanoString Seek to Identify I-O Responders in Rich Companion Dx Deal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Feb
2016
One Way to Improve Clinical Trials: A Yelp-Style Rating System
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Feb
2016
Califf Confirmed, Obama Elevates Precision Med, and 47 Grabs $75M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Feb
2016
Active VCs vs. Zombies: Dysfunctional Boards That Mess With M&A
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Feb
2016
Intercept Rumors, Alnylam’s $200M Factory, and Some Precious Ebola Antibodies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Feb
2016
‘Quit Whining’ and 11 Other Ways Industry Should Communicate Better
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Feb
2016
Zika Fear, Stock Jitters, and Soul-Searching on Drug Prices
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Feb
2016
No, CRISPR-Cas Won’t Save The Day For AgBio. A Twist on The GMO Debate Might
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Feb
2016
Why Patents Are Sometimes Overrated
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Feb
2016
Are You Ready for Some Football? Maybe Yes, Maybe No
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Feb
2016
As the Smirk Turns, FDA’s Opioid Plan, And A Gene Editing IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Feb
2016
A Short History of Cures for Hepatitis C
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jan
2016
Merck’s HCV Contender, Red Tickers, and Research Parasites
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Jan
2016
Time to Renew, February Subscribers!
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jan
2016
Big Pharma May Be a Dinosaur, But It Can Move Fast When It Wants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2016
A Clinical Disaster in France, Alkermes Whiffs, and the DMD Anti-Climax
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jan
2016
Should Basic Lab Experiments Be Blinded to Chip Away at the Reproducibility Problem?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.